decreased significantly from baseline by 1.9% to 2.7% in Hispanic/Latino patients and 1.7% to 2.5% in non-Hispanic/Latino patients treated with tirzepatide.
Body weight decreased significantly in Hispanic/Latino patients by 5.3 kg to 12.4 kg and in non-Hispanic/Latino patients by 6.5 kg to 17.1 kg.
Treatment-emergent adverse events occurred at similar rates in both Hispanic/Latino and non-Hispanic/Latino subgroups, primarily involving gastrointestinal disorders.
The incidence of hypoglycemia was low across both ethnic groups.
Efficacy and safety trends were consistent between Hispanic/Latino and non-Hispanic/Latino patients within the overall trial populations.
Simplified
CONTEXT: Efficacy and safety of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, have been studied in patients with type 2 diabetes in the global phase 3 SURPASS program.
OBJECTIVE: This work aimed to assess the efficacy and safety of tirzepatide in Hispanic/Latino and non-Hispanic/Latino patients in SURPASS-1 to -4 clinical trials.
METHODS: A total of 5679 patients were included, 2895 of self-reported Hispanic/Latino ethnicity, in this exploratory analysis of SURPASS-1 to -4 trial data. Interventions included tirzepatide 5, 10, or 15 mg, placebo, or active comparator (semaglutide 1 mg, insulin degludec, and insulin glargine). Change in glycated hemoglobin A1c () and body weight from baseline to week 40 (SURPASS-1 and -2) and to week 52 (SURPASS-3 and -4), and other efficacy and safety outcomes were evaluated within Hispanic/Latino and non-Hispanic/Latino subgroups.
RESULTS: Among Hispanic/Latino and non-Hispanic/Latino patients treated with tirzepatide, respectively, HbA1c decreased significantly from baseline, ranging from 1.9% to 2.7% and 1.7% to 2.5%, and body weight decreased significantly from baseline, ranging from 5.3 kg to 12.4 and 6.5 kg to 17.1 kg (both P < .05) vs comparators across all trials. Subgroup trends were consistent with the overall trial populations. Treatment-emergent adverse events were reported in similar proportions across the subgroups and were primarily gastrointestinal disorders. The incidence of hypoglycemia was low.
CONCLUSION: Tirzepatide significatively reduced HbA1c and body weight in Hispanic/Latino and non-Hispanic/Latino patients. Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and within the overall trial populations.
Key numbers
1.9% to 2.7%
Reduction
Reduction from baseline in Hispanic/Latino patients.
5.3 kg to 12.4 kg
Body Weight Reduction
Change from baseline in Hispanic/Latino patients.
6.5 kg to 17.1 kg
Body Weight Reduction
Change from baseline in non-Hispanic/Latino patients.
Full Text
We can’t show the full text here under this license.
